• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
MYX
Click for more information
7.18% $4.48

MAYNE PHARMA GROUP LIMITED - Announcements

Market Cap $393.8M  ! watchlist Created with Sketch. Add to my watchlist

Mayne Pharma Group Limited is an Australia-based specialty pharmaceutical company focused... Mayne Pharma Group Limited is an Australia-based specialty pharmaceutical company focused on commercializing novel pharmaceuticals. The Company also provides contract development and manufacturing services to clients worldwide. The Company’s segments include Women’s Health, Dermatology, and International. The Women’s Health segment distributes women’s health branded products in the United States. This segment includes NEXTSTELLIS, ANNOVERA, BIJUVA, IMVEXXY and branded pre-natal vitamins. The Dermatology segment distributes established dermatology products in the United States. The International segment is engaged in the manufacture and sale of branded and generic pharmaceutical products globally and the provision of contract development and manufacturing services to third party customers. The Company's products include ACTIKERALL Solution, ASTRIX Capsules and Tablets, MAGNOPLASM Paste and SPLINTEX Splinter Removal Gel, and ANNOVERA Vaginal Ring, among others.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
Filters [Clear]
  • Price Sensitive: Yes
MYX 2019 Half Year Investor PresentationPRICE SENSITIVE22/02/19
MYX 2019 Half Year Media ReleasePRICE SENSITIVE22/02/19
MYX Half Year AccountsPRICE SENSITIVE22/02/19
MYX Tolsura (SUBA-itraconazole) capsule now launched in the USPRICE SENSITIVE30/01/19
MYX FDA approval of Tolsura (SUBA-itraconazole) capsulesPRICE SENSITIVE12/12/18
MYX 2018 AGM CEO's SpeechPRICE SENSITIVE29/11/18
MYX 2018 AGM Chairman's AddressPRICE SENSITIVE29/11/18
MYX 2018 Full Year Results Investor PresentationPRICE SENSITIVE24/08/18
MYX 2018 Full Year Results Media ReleasePRICE SENSITIVE24/08/18
MYX Full Year Statutory AccountsPRICE SENSITIVE24/08/18
MYX Mayne Pharma acquires generic Efudex in the USPRICE SENSITIVE23/07/18
MYX SUBA-Itraconazole NDA accepted for review by US FDAPRICE SENSITIVE02/05/18
MYX Mayne Pharma opens new US manufacturing facilityPRICE SENSITIVE18/04/18
MYX Mayne Pharma launches Amiodarone 200mg tablets in the USPRICE SENSITIVE17/04/18
MYX Mayne Pharma's generic NuvaRing accepted for filing by FDAPRICE SENSITIVE20/03/18
MYX Mayne Pharma launches doxycycline IR capsules in the USPRICE SENSITIVE16/03/18
MYX First generic launch of Ritalin LA 10mg capsules in the USPRICE SENSITIVE01/03/18
MYX 2018 Half Year Investor PresentationPRICE SENSITIVE23/02/18
MYX 2018 Half Year Media ReleasePRICE SENSITIVE23/02/18
MYX Half Yearly Report and AccountsPRICE SENSITIVE23/02/18
MYX 2017 CEO's SpeechPRICE SENSITIVE28/11/17
MYX Mayne Pharma launches clozapine tablets in the USPRICE SENSITIVE09/11/17
MYX Mayne Pharma adds two products to its Australian portfolioPRICE SENSITIVE15/09/17
MYX Preliminary Final ReportPRICE SENSITIVE25/08/17
MYX Mayne Pharma market updatePRICE SENSITIVE08/08/17
MYX FDA approval and first generic launch of Acticlate tabletsPRICE SENSITIVE15/06/17
MYX Response to ASX Aware LetterPRICE SENSITIVE04/05/17
MYX Clarification statementPRICE SENSITIVE02/05/17
MYX Mayne Pharma acquires rights to generic Duragesic in the USPRICE SENSITIVE09/03/17
MYX License and supply agreement for generic Nuvaring in the USPRICE SENSITIVE28/02/17
MYX 2017 Half Year Media ReleasePRICE SENSITIVE24/02/17
MYX Half Yearly Report and AccountsPRICE SENSITIVE24/02/17
MYX Mayne Pharma launches Butalbital / APAP tablets in the USPRICE SENSITIVE16/02/17
MYX Mayne Pharma launches Amiodarone 100mg tabletsPRICE SENSITIVE13/01/17
MYX Mayne Pharma launches Fabior and Sorilux in the USPRICE SENSITIVE11/01/17
MYX Update on Status of DOJ InvestigationPRICE SENSITIVE16/12/16
MYX Update on Status of DOJ InvestigationPRICE SENSITIVE04/11/16
MYX MYX launches generic MS Contin (morphine sulfate) tablets-MYX.AX PRICE SENSITIVE03/11/16
MYX MYX launches generic MS Contin (morphine sulfate) tabletsPRICE SENSITIVE03/11/16
MYX 1st generic proprietary product shipped to US, temozolomide,MYX-IDT.AX PRICE SENSITIVE02/11/16
MYX MYX launches generic Entocort EC (Budesonide) capsules-MYX.AX PRICE SENSITIVE27/10/16
MYX Appendix 4E, Directors Report and Financial Statements-MYX.AX PRICE SENSITIVE28/08/16
MYX Appendix 4E, Directors Report and Financial Statements-MYX.AX PRICE SENSITIVE26/08/16
MYX MYX announces acquisition of US foam dermatology assets-MYX.AX PRICE SENSITIVE18/08/16
MYX MYX announces settlement from patent infringement case-MYX.AX PRICE SENSITIVE29/07/16
MYX Completion institutional entitlement offer and placement-MYX.AX PRICE SENSITIVE30/06/16
MYX MYX announces acquisition of US generic product portfolio-MYX.AX PRICE SENSITIVE28/06/16
MYX Trading Halt-MYX.AX PRICE SENSITIVE28/06/16
MYX MYX receives first generic approval of Tikosyn capsules-MYX.AX PRICE SENSITIVE07/06/16
MYX Mayne Pharma receives FDA approval for Doryx MPC tablets-MYX.AX PRICE SENSITIVE23/05/16
MYX Half Yearly Report and AccountsPRICE SENSITIVE26/02/16
MYX 2015 Appendix 4E & Annual ReportPRICE SENSITIVE28/08/15
MYX Mayne announces strategic investment in US facilitiesPRICE SENSITIVE28/08/15
MYX Mayne Pharma recipient of A$4m Government GrantPRICE SENSITIVE04/08/15
MYX Mayne Pharma successfully completes US$125m debt financingPRICE SENSITIVE25/06/15
MYX New equity investment in Hedgepath PharmaceuticalsPRICE SENSITIVE18/05/15
MYX US Oxycodone franchise restructure and Doryx re-launchPRICE SENSITIVE04/05/15
MYX Half Year Results and AccountsPRICE SENSITIVE26/02/15
MYX Pfizer withdraws US Tikosyn Litigation against Mayne PharmaPRICE SENSITIVE25/02/15
MYX Completion institutional entitlement offer and placementPRICE SENSITIVE12/02/15
MYX Mayne Pharma announces acquisition of DoryxPRICE SENSITIVE10/02/15
MYX Trading HaltPRICE SENSITIVE10/02/15
MYX Mayne Pharma announces US Paragraph IV ChallengePRICE SENSITIVE18/11/14
MYX 2014 Appendix 4E & Annual ReportPRICE SENSITIVE27/08/14
MYX Mayne Pharma out-licenses IP to Hedgepath PharmaceuticalsPRICE SENSITIVE25/06/14
MYXHalf Yearly Report and AccountsPRICE SENSITIVE26/02/14
MYXCompletion of placementPRICE SENSITIVE13/02/14
MYXMayne Pharma announces acquisition of LORCET & ESGICPRICE SENSITIVE12/02/14
MYXTrading HaltPRICE SENSITIVE12/02/14
MYXMayne Pharma results and product updatePRICE SENSITIVE06/02/14
MYXMYX announces US agreement for Itraconazole in CancerPRICE SENSITIVE11/09/13
MYX2013 Full Year Results Appendix 4EPRICE SENSITIVE27/08/13
MYXMayne Pharma Signs European SUBACAP Distribution AgreementsPRICE SENSITIVE09/08/13
MYXMayne Pharma Launches Generic DoryxPRICE SENSITIVE09/07/13
MYXMayne Pharma announces acquisition of LibertasPRICE SENSITIVE02/07/13
MYXFDA Approval of New 200mg Doryx TabletPRICE SENSITIVE12/04/13
MYX2013 Half Year Media ReleasePRICE SENSITIVE27/02/13
MYXHalf Yearly Report and AccountsPRICE SENSITIVE27/02/13
MYXCompletion of placementPRICE SENSITIVE17/12/12
MYXMayne Pharma announces the acquisition of KapanolPRICE SENSITIVE14/12/12
MYXTrading HaltPRICE SENSITIVE14/12/12
MYX2012 AGM CEO's SpeechPRICE SENSITIVE09/11/12
MYXMayne Pharma announces in-licensing agreementPRICE SENSITIVE01/11/12
MYXRetail Offer BookletPRICE SENSITIVE12/10/12
MYXCompletion institutional entitlement/unconditional placementPRICE SENSITIVE08/10/12
MYXMayne Pharma Announces the Acquisition of Metrics, Inc.PRICE SENSITIVE04/10/12
MYXTrading HaltPRICE SENSITIVE04/10/12
MYXMedia SpeculationPRICE SENSITIVE24/09/12
MYXMedia SpeculationPRICE SENSITIVE24/09/12
MYXPreliminary Final ReportPRICE SENSITIVE21/08/12
MYXMayne Pharma announces SUBACAP approvablePRICE SENSITIVE21/06/12
MYXUS Court decides on Doryx 161 PatentPRICE SENSITIVE01/05/12
MYXHalf Yearly Report and AccountsPRICE SENSITIVE28/02/12
MYXDoryx Generic UpdatePRICE SENSITIVE10/02/12
MYXSUBACAP UpdatePRICE SENSITIVE15/12/11
MYXDoryx Generic UpdatePRICE SENSITIVE13/12/11
MYXMYX APPOINTS SCOTT RICHARDS AS CEOPRICE SENSITIVE02/12/11
MYXChairman's Address to ShareholdersPRICE SENSITIVE23/11/11
MYXDoryx Generic UpdatePRICE SENSITIVE22/09/11
MYXFDA Approval Of New Dual-Scored 150mg Doryx TabletPRICE SENSITIVE14/09/11
MYX 2019 Half Year Investor Presentation
22/02/19PRICE SENSITIVE
MYX 2019 Half Year Media Release
22/02/19PRICE SENSITIVE
MYX Half Year Accounts
22/02/19PRICE SENSITIVE
MYX Tolsura (SUBA-itraconazole) capsule now launched in the US
30/01/19PRICE SENSITIVE
MYX FDA approval of Tolsura (SUBA-itraconazole) capsules
12/12/18PRICE SENSITIVE
MYX 2018 AGM CEO's Speech
29/11/18PRICE SENSITIVE
MYX 2018 AGM Chairman's Address
29/11/18PRICE SENSITIVE
MYX 2018 Full Year Results Investor Presentation
24/08/18PRICE SENSITIVE
MYX 2018 Full Year Results Media Release
24/08/18PRICE SENSITIVE
MYX Full Year Statutory Accounts
24/08/18PRICE SENSITIVE
MYX Mayne Pharma acquires generic Efudex in the US
23/07/18PRICE SENSITIVE
MYX SUBA-Itraconazole NDA accepted for review by US FDA
02/05/18PRICE SENSITIVE
MYX Mayne Pharma opens new US manufacturing facility
18/04/18PRICE SENSITIVE
MYX Mayne Pharma launches Amiodarone 200mg tablets in the US
17/04/18PRICE SENSITIVE
MYX Mayne Pharma's generic NuvaRing accepted for filing by FDA
20/03/18PRICE SENSITIVE
MYX Mayne Pharma launches doxycycline IR capsules in the US
16/03/18PRICE SENSITIVE
MYX First generic launch of Ritalin LA 10mg capsules in the US
01/03/18PRICE SENSITIVE
MYX 2018 Half Year Investor Presentation
23/02/18PRICE SENSITIVE
MYX 2018 Half Year Media Release
23/02/18PRICE SENSITIVE
MYX Half Yearly Report and Accounts
23/02/18PRICE SENSITIVE
MYX 2017 CEO's Speech
28/11/17PRICE SENSITIVE
MYX Mayne Pharma launches clozapine tablets in the US
09/11/17PRICE SENSITIVE
MYX Mayne Pharma adds two products to its Australian portfolio
15/09/17PRICE SENSITIVE
MYX Preliminary Final Report
25/08/17PRICE SENSITIVE
MYX Mayne Pharma market update
08/08/17PRICE SENSITIVE
MYX FDA approval and first generic launch of Acticlate tablets
15/06/17PRICE SENSITIVE
MYX Response to ASX Aware Letter
04/05/17PRICE SENSITIVE
MYX Clarification statement
02/05/17PRICE SENSITIVE
MYX Mayne Pharma acquires rights to generic Duragesic in the US
09/03/17PRICE SENSITIVE
MYX License and supply agreement for generic Nuvaring in the US
28/02/17PRICE SENSITIVE
MYX 2017 Half Year Media Release
24/02/17PRICE SENSITIVE
MYX Half Yearly Report and Accounts
24/02/17PRICE SENSITIVE
MYX Mayne Pharma launches Butalbital / APAP tablets in the US
16/02/17PRICE SENSITIVE
MYX Mayne Pharma launches Amiodarone 100mg tablets
13/01/17PRICE SENSITIVE
MYX Mayne Pharma launches Fabior and Sorilux in the US
11/01/17PRICE SENSITIVE
MYX Update on Status of DOJ Investigation
16/12/16PRICE SENSITIVE
MYX Update on Status of DOJ Investigation
04/11/16PRICE SENSITIVE
MYX MYX launches generic MS Contin (morphine sulfate) tablets-MYX.AX
03/11/16PRICE SENSITIVE
MYX MYX launches generic MS Contin (morphine sulfate) tablets
03/11/16PRICE SENSITIVE
MYX 1st generic proprietary product shipped to US, temozolomide,MYX-IDT.AX
02/11/16PRICE SENSITIVE
MYX MYX launches generic Entocort EC (Budesonide) capsules-MYX.AX
27/10/16PRICE SENSITIVE
MYX Appendix 4E, Directors Report and Financial Statements-MYX.AX
28/08/16PRICE SENSITIVE
MYX Appendix 4E, Directors Report and Financial Statements-MYX.AX
26/08/16PRICE SENSITIVE
MYX MYX announces acquisition of US foam dermatology assets-MYX.AX
18/08/16PRICE SENSITIVE
MYX MYX announces settlement from patent infringement case-MYX.AX
29/07/16PRICE SENSITIVE
MYX Completion institutional entitlement offer and placement-MYX.AX
30/06/16PRICE SENSITIVE
MYX MYX announces acquisition of US generic product portfolio-MYX.AX
28/06/16PRICE SENSITIVE
MYX Trading Halt-MYX.AX
28/06/16PRICE SENSITIVE
MYX MYX receives first generic approval of Tikosyn capsules-MYX.AX
07/06/16PRICE SENSITIVE
MYX Mayne Pharma receives FDA approval for Doryx MPC tablets-MYX.AX
23/05/16PRICE SENSITIVE
MYX Half Yearly Report and Accounts
26/02/16PRICE SENSITIVE
MYX 2015 Appendix 4E & Annual Report
28/08/15PRICE SENSITIVE
MYX Mayne announces strategic investment in US facilities
28/08/15PRICE SENSITIVE
MYX Mayne Pharma recipient of A$4m Government Grant
04/08/15PRICE SENSITIVE
MYX Mayne Pharma successfully completes US$125m debt financing
25/06/15PRICE SENSITIVE
MYX New equity investment in Hedgepath Pharmaceuticals
18/05/15PRICE SENSITIVE
MYX US Oxycodone franchise restructure and Doryx re-launch
04/05/15PRICE SENSITIVE
MYX Half Year Results and Accounts
26/02/15PRICE SENSITIVE
MYX Pfizer withdraws US Tikosyn Litigation against Mayne Pharma
25/02/15PRICE SENSITIVE
MYX Completion institutional entitlement offer and placement
12/02/15PRICE SENSITIVE
MYX Mayne Pharma announces acquisition of Doryx
10/02/15PRICE SENSITIVE
MYX Trading Halt
10/02/15PRICE SENSITIVE
MYX Mayne Pharma announces US Paragraph IV Challenge
18/11/14PRICE SENSITIVE
MYX 2014 Appendix 4E & Annual Report
27/08/14PRICE SENSITIVE
MYX Mayne Pharma out-licenses IP to Hedgepath Pharmaceuticals
25/06/14PRICE SENSITIVE
MYXHalf Yearly Report and Accounts
26/02/14PRICE SENSITIVE
MYXCompletion of placement
13/02/14PRICE SENSITIVE
MYXMayne Pharma announces acquisition of LORCET & ESGIC
12/02/14PRICE SENSITIVE
MYXTrading Halt
12/02/14PRICE SENSITIVE
MYXMayne Pharma results and product update
06/02/14PRICE SENSITIVE
MYXMYX announces US agreement for Itraconazole in Cancer
11/09/13PRICE SENSITIVE
MYX2013 Full Year Results Appendix 4E
27/08/13PRICE SENSITIVE
MYXMayne Pharma Signs European SUBACAP Distribution Agreements
09/08/13PRICE SENSITIVE
MYXMayne Pharma Launches Generic Doryx
09/07/13PRICE SENSITIVE
MYXMayne Pharma announces acquisition of Libertas
02/07/13PRICE SENSITIVE
MYXFDA Approval of New 200mg Doryx Tablet
12/04/13PRICE SENSITIVE
MYX2013 Half Year Media Release
27/02/13PRICE SENSITIVE
MYXHalf Yearly Report and Accounts
27/02/13PRICE SENSITIVE
MYXCompletion of placement
17/12/12PRICE SENSITIVE
MYXMayne Pharma announces the acquisition of Kapanol
14/12/12PRICE SENSITIVE
MYXTrading Halt
14/12/12PRICE SENSITIVE
MYX2012 AGM CEO's Speech
09/11/12PRICE SENSITIVE
MYXMayne Pharma announces in-licensing agreement
01/11/12PRICE SENSITIVE
MYXRetail Offer Booklet
12/10/12PRICE SENSITIVE
MYXCompletion institutional entitlement/unconditional placement
08/10/12PRICE SENSITIVE
MYXMayne Pharma Announces the Acquisition of Metrics, Inc.
04/10/12PRICE SENSITIVE
MYXTrading Halt
04/10/12PRICE SENSITIVE
MYXMedia Speculation
24/09/12PRICE SENSITIVE
MYXMedia Speculation
24/09/12PRICE SENSITIVE
MYXPreliminary Final Report
21/08/12PRICE SENSITIVE
MYXMayne Pharma announces SUBACAP approvable
21/06/12PRICE SENSITIVE
MYXUS Court decides on Doryx 161 Patent
01/05/12PRICE SENSITIVE
MYXHalf Yearly Report and Accounts
28/02/12PRICE SENSITIVE
MYXDoryx Generic Update
10/02/12PRICE SENSITIVE
MYXSUBACAP Update
15/12/11PRICE SENSITIVE
MYXDoryx Generic Update
13/12/11PRICE SENSITIVE
MYXMYX APPOINTS SCOTT RICHARDS AS CEO
02/12/11PRICE SENSITIVE
MYXChairman's Address to Shareholders
23/11/11PRICE SENSITIVE
MYXDoryx Generic Update
22/09/11PRICE SENSITIVE
MYXFDA Approval Of New Dual-Scored 150mg Doryx Tablet
14/09/11PRICE SENSITIVE
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
$4.48 		Change
0.300(7.18%) 		Mkt cap ! $393.8M
Open High Low Value Volume
$4.22 $4.50 $4.18 $1.134M 259.5K

Buyers (Bids)

No. Vol. Price($)
1 708 $4.43
 

Sellers (Offers)

Price($) Vol. No.
$4.50 1182 1
View Market Depth
Last trade - 16.10pm 22/11/2024 (20 minute delay) ?
Last
$4.48 		  Change
0.300 ( 7.09 %)
Open High Low Volume
$4.23 $4.49 $4.17 95547
Last updated 15.59pm 22/11/2024 ?
MYX (ASX) Chart

Top Stories

Week 47 Wrap: HotCopper users' most watched; Brent lifts on Putin's scary letter; RFK dents CSL

Welcome to the end of another week. Let's start with what HotCopper users have been watching and discussing.
To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
Panic, paranoia, and gangland politics: HotCopper users react to Dubber's missing $26M HotCopper users have reacted to overnight reports Dubber has seen $26M disappear from its coffers due to organised crime links.
HotCopper Highlights: Your most watched stocks for Week 47, 2024 In this segment we’ll look at the top stocks HotCopper users have been watching, and discussing, through Week 47. Let’s get into it. 
Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.